Nutriband Inc.

NASDAQ:NTRB

Biotechnology

Healthcare
$5.59 +22.32%

+$0.85 today

Market cap
$67.95M
Beta
1.97
P/E (TTM)
-1.8
EPS (TTM)
-$0.66
52W Low $2.80High $8.63

Volume 0.02M

Average 0.01M

NTRB EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Nutriband Inc.NASDAQ: NTRB

EBITDA · Q1 FY2026 · quarter ended Apr 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$1.2M, compared with -$1.33M a year earlier. Trailing-twelve-month EBITDA was -$7.89M.

Context

  • EBITDA amounted to 393.5% of revenue in FY2025, down 82.1 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of $23.96M (+399.0%) for the fiscal year ending Jan 2027, a step up from the +21.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterApr 2026
-$1.2M-29.8% QoQ
Last fiscal yearJan 2026
-$8.01M+21.3% YoY
LTMApr 2026
-$7.89M+18.5% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.3%——
1 year+21.3%+399.0%+377.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(8.01M) USD
Year-over-year change
+21.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How NTRB compares with its peers on the latest reported figures

  • NTRB's LTM Apr 2026 EBITDA of -$7.89M is the 2nd highest of the 9 companies compared; the peer median is -$48.6M.
  • Its year-over-year change of +18.5% is the 2nd highest of 8, against a peer median of +0.7%.
  • EBITDA amounts to 437.7% of revenue for NTRB, versus a peer median of 1298.7%.
NTRB Competitors Peer median
EBITDA for NTRB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$148.02M +264.5%—223.7%
NTRBNutriband Inc.LTM Apr 2026-$7.89M +18.5%—437.7%
GANXGain Therapeutics, Inc.LTM Mar 2026-$20.2M +0.1%——
ADAGAdagene Inc.LTM Jun 2024-$36.06M ——4420.7%
XBITXBiotech Inc.LTM Mar 2026-$38.33M -3.1%——
RLMDRelmada Therapeutics, Inc.LTM Mar 2026-$58.88M -297.6%——
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026-$82.08M +0.7%——
ACETAdicet Bio, Inc.LTM Mar 2026-$102.73M +7.3%——
TCRXTScan Therapeutics, Inc.LTM Mar 2026-$118.65M +4.8%—1298.7%
Peer median (excluding NTRB) -$48.6M+0.7%—1298.7%

Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Jan 2024
FY2024
Jan 2025
FY2025
Jan 2026
Revenue1.42M2.08M2.09M2.14M2.04M
Cost of Revenue917.84K1.33M1.22M1.44M1.47M
Gross Profit504.31K750.41K862.11K699.3K566.31K
Gross Margin35.5%36.1%41.3%32.7%27.8%
Research & Development411.38K982.23K1.96M3.12M1.89M
Selling, General & Admin4.02M3.92M3.77M4.27M6.99M
Operating Expenses4.43M4.9M5.73M7.39M8.88M
Depreciation & Amortization318.26K368.96K287.72K285.05K193.8K
EBITDA(5.74M)(4.11M)(5.12M)(10.18M)(8.01M)
EBITDA Margin-403.6%-197.5%-245.6%-475.5%-393.5%
Operating Income(3.93M)(4.15M)(4.87M)(6.69M)(8.32M)
Operating Margin-276.3%-199.5%-233.6%-312.6%-408.4%
Interest Income0016.85K191.67K0
Interest Expense118.42K8.29K75.82K21.41K22.54K
Other Income / Expenses(2.25M)(335.62K)(613.39K)(3.79M)88.33K
Income Before Tax(6.18M)(4.48M)(5.49M)(10.48M)(8.23M)
Pre-Tax Margin-434.3%-215.6%-263.0%-489.9%-404.1%
Income Tax Expense00000
Net Income(8.42M)(4.81M)(5.49M)(10.48M)(8.23M)
Net Margin-592.2%-231.3%-263.0%-489.9%-404.1%
EPS (Basic)(1.06)(0.57)(0.69)(0.99)(2.58)
EPS (Diluted)(1.06)(0.57)(0.69)(0.99)(2.58)
Weighted Avg Shares7.93M8.46M7.95M10.61M11.64M
Weighted Avg Shares (Diluted)7.93M8.46M7.95M10.61M11.64M

Nutriband Inc.

NASDAQ:NTRB

Intrinsic Alpha fair value

Locked

Current Price

$5.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.